United Therapeutics (NASDAQ:UTHR) EVP Sells $4,787,606.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $576.82, for a total transaction of $4,787,606.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $26,056,113.04. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Trading Up 0.5%

United Therapeutics stock traded up $2.93 during midday trading on Thursday, hitting $580.51. The stock had a trading volume of 446,672 shares, compared to its average volume of 497,137. The firm’s fifty day moving average is $522.64 and its two-hundred day moving average is $487.71. The company has a market capitalization of $25.44 billion, a PE ratio of 20.81, a P/E/G ratio of 1.65 and a beta of 0.75. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $607.89.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.19 EPS. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on UTHR. Morgan Stanley increased their target price on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Oppenheimer increased their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Royal Bank Of Canada upped their price target on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, HC Wainwright upped their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Ten investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $601.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Torren Management LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at approximately $26,000. Activest Wealth Management boosted its position in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB boosted its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in shares of United Therapeutics during the 4th quarter valued at approximately $48,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.